ArticleClinical and experimental nephrology2026
Detection of mulberry bodies using molecular imaging flow cytometry.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFabry disease is a hereditary disorder that leads to the accumulation of glycolipids, such as globotriaosylceramide, because of the absence or decreased activity of the enzyme alpha-galactosidase A, causing various organ dysfunctions. Urinary mulberry bodies (MBs) are specific markers of Fabry disease and can be identified in urinary sediments through microscopic visual evaluation. However, MBs are present in small quantities in urine, and some are difficult to distinguish morphologically from other urinary components, necessitating a highly accurate and objective automated detection method. Here, we examined the detection of MBs using molecular imaging flow cytometry (MI-FCM).
methodsUrine samples from patients with and without Fabry disease were analyzed by MI-FCM for MB detection. Microscopy was used as a control method to identify MBs.
resultsMI-FCM detected MBs in 33 of 36 Fabry disease patients (sensitivity: 91.7%) and did not detect MBs in any of the nine non-Fabry patients (specificity: 100%). In comparison, visual inspection under an optical microscope detected MBs in 23 of 36 Fabry disease patients (sensitivity: 63.9%), confirming that MI-FCM provided more accurate detection. MBs were detected by MI-FCM in 29 of 30 patients with negative urinary protein.
conclusionMI-FCM frequently detected MBs in Fabry disease patients, even before the onset of renal dysfunction. Screening for MBs may be useful for the early detection of Fabry disease.
Indexed as
Identifiers
41266682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.